Chemistry:GRC-6211
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C22H20FN3O2 |
| Molar mass | 377.419 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
GRC-6211 is a drug developed by Glenmark Pharmaceuticals which acts as a potent and selective antagonist for the TRPV1 receptor. It has analgesic and antiinflammatory effects and reached Phase IIb human trials, but was ultimately discontinued from development as a medicine, though it continues to have applications in scientific research.[1][2][3]
References
- ↑ "GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models". The Journal of Urology 181 (1): 379–86. January 2009. doi:10.1016/j.juro.2008.08.121. PMID 19010489.
- ↑ "Analgesic potential of TRPV1 antagonists". Biochemical Pharmacology 78 (3): 211–6. August 2009. doi:10.1016/j.bcp.2009.02.014. PMID 19481638.
- ↑ "Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist". Autonomic Neuroscience 166 (1–2): 35–8. January 2012. doi:10.1016/j.autneu.2011.09.005. PMID 22037502.
 |  |
